Symyx in Discussions with New Suitor after Bidding Climbs to $6.75 Per Share

The proposed merger between Accelrys and Symyx may have hit a snag this week as Symyx disclosed that it will "engage in discussions" with an undisclosed firm that has made a competing offer.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.